Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab

por Fink, A M, Böttcher, S, Ritgen, M, Fischer, K, Pflug, N, Eichhorst, B, Wendtner, C-M, Winkler, D, Bühler, A, Zenz, T, Staib, P, Mayer, J, Hensel, M, Hopfinger, G, Wenger, M, Fingerle-Rowson, G, Döhner, H, Kneba, M, Stilgenbauer, S, Busch, R, Hallek, M
Publicado 2013

Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL

por Schrader, A., Crispatzu, G., Oberbeck, S., Mayer, P., Pützer, S., von Jan, J., Vasyutina, E., Warner, K., Weit, N., Pflug, N., Braun, T., Andersson, E. I., Yadav, B., Riabinska, A., Maurer, B., Ventura Ferreira, M. S., Beier, F., Altmüller, J., Lanasa, M., Herling, C. D., Haferlach, T., Stilgenbauer, S., Hopfinger, G., Peifer, M., Brümmendorf, T. H., Nürnberg, P., Elenitoba-Johnson, K. S. J., Zha, S., Hallek, M., Moriggl, R., Reinhardt, H. C., Stern, M.-H., Mustjoki, S., Newrzela, S., Frommolt, P., Herling, M.
Publicado 2018